These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 19530741)
1. Risk of fractures with glitazones: a critical review of the evidence to date. Bodmer M; Meier C; Kraenzlin ME; Meier CR Drug Saf; 2009; 32(7):539-47. PubMed ID: 19530741 [TBL] [Abstract][Full Text] [Related]
2. [Thiazolidinediones and skeletal health]. Meier C; Bodmer M; Meier CR; Kraenzlin ME Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930 [TBL] [Abstract][Full Text] [Related]
4. Bone loss and fracture risk associated with thiazolidinedione therapy. Riche DM; King ST Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635 [TBL] [Abstract][Full Text] [Related]
5. Skeletal consequences of thiazolidinedione therapy. Grey A Osteoporos Int; 2008 Feb; 19(2):129-37. PubMed ID: 17901911 [TBL] [Abstract][Full Text] [Related]
6. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Lecka-Czernik B Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203 [TBL] [Abstract][Full Text] [Related]
7. Bone effects of glitazones and other anti-diabetic drugs. Rejnmark L Curr Drug Saf; 2008 Sep; 3(3):194-8. PubMed ID: 18691001 [TBL] [Abstract][Full Text] [Related]
8. Antidiabetic therapy effects on bone metabolism and fracture risk. Montagnani A; Gonnelli S Diabetes Obes Metab; 2013 Sep; 15(9):784-91. PubMed ID: 23368527 [TBL] [Abstract][Full Text] [Related]
9. Fracture risk is a class effect of glitazones. Short R BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363794 [No Abstract] [Full Text] [Related]
10. The effect of thiazolidinediones on BMD and osteoporosis. McDonough AK; Rosenthal RS; Cao X; Saag KG Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700 [TBL] [Abstract][Full Text] [Related]
11. Bone as a target of type 2 diabetes treatment. Lecka-Czernik B Curr Opin Investig Drugs; 2009 Oct; 10(10):1085-90. PubMed ID: 19777397 [TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Betteridge DJ Diabet Med; 2011 Jul; 28(7):759-71. PubMed ID: 21672000 [TBL] [Abstract][Full Text] [Related]
14. Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Wolverton D; Blair MM Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778 [TBL] [Abstract][Full Text] [Related]
15. Diabetes drug pioglitazone (Actos): risk of fracture. Meymeh RH; Wooltorton E CMAJ; 2007 Sep; 177(7):723-4. PubMed ID: 17823139 [No Abstract] [Full Text] [Related]
16. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Soccio RE; Chen ER; Lazar MA Cell Metab; 2014 Oct; 20(4):573-91. PubMed ID: 25242225 [TBL] [Abstract][Full Text] [Related]
17. Glitazones in type 2 diabetes: an update. Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615 [TBL] [Abstract][Full Text] [Related]
18. [Diabetes mellitus, thiazolidinediones and fractures: an unfinished story]. Silva AG; Lazaretti-Castro M Arq Bras Endocrinol Metabol; 2010 Jun; 54(4):345-51. PubMed ID: 20625645 [TBL] [Abstract][Full Text] [Related]
19. Glitazone use associated with diabetic macular edema. Fong DS; Contreras R Am J Ophthalmol; 2009 Apr; 147(4):583-586.e1. PubMed ID: 19181303 [TBL] [Abstract][Full Text] [Related]